EPIGENE.COM Trademark

Trademark Overview


On Friday, July 21, 2006, a trademark application was filed for EPIGENE.COM with the United States Patent and Trademark Office. The USPTO has given the EPIGENE.COM trademark a serial number of 78935316. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 17, 2011. This trademark is owned by Epigenesis Pharmaceuticals, LLC. The EPIGENE.COM trademark is filed in the Pharmaceutical Products category with the following description:

medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory...
epigene.com

General Information


Serial Number78935316
Word MarkEPIGENE.COM
Filing DateFriday, July 21, 2006
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 17, 2011
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 25, 2007

Trademark Statements


Disclaimer with Predetermined Text".COM"
Goods and Servicesmedical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ards), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (svt), adenosine stress tests, infantile respiratory distress syndrome (infantile rds), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (copd), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 26, 2006
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEpigenesis Pharmaceuticals, LLC
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCranbury, NJ 08512

Party NameEpigenesis Pharmaceuticals, LLC
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCranbury, NJ 08512

Trademark Events


Event DateEvent Description
Tuesday, January 18, 2011ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, January 17, 2011ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 26, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 25, 2010EXTENSION 5 GRANTED
Monday, May 17, 2010EXTENSION 5 FILED
Monday, May 17, 2010TEAS EXTENSION RECEIVED
Wednesday, December 9, 2009EXTENSION 4 GRANTED
Wednesday, December 2, 2009EXTENSION 4 FILED
Wednesday, December 2, 2009TEAS EXTENSION RECEIVED
Tuesday, June 30, 2009EXTENSION 3 GRANTED
Monday, June 8, 2009EXTENSION 3 FILED
Tuesday, June 30, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 8, 2009TEAS EXTENSION RECEIVED
Monday, December 1, 2008EXTENSION 2 GRANTED
Monday, December 1, 2008EXTENSION 2 FILED
Monday, December 1, 2008TEAS EXTENSION RECEIVED
Wednesday, June 4, 2008EXTENSION 1 GRANTED
Wednesday, June 4, 2008EXTENSION 1 FILED
Wednesday, June 4, 2008TEAS EXTENSION RECEIVED
Tuesday, December 18, 2007NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 25, 2007PUBLISHED FOR OPPOSITION
Wednesday, September 5, 2007NOTICE OF PUBLICATION
Monday, August 20, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, August 20, 2007ASSIGNED TO LIE
Thursday, July 5, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 28, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 28, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 28, 2007TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 29, 2006NON-FINAL ACTION E-MAILED
Friday, December 29, 2006NON-FINAL ACTION WRITTEN
Sunday, December 17, 2006ASSIGNED TO EXAMINER
Wednesday, July 26, 2006NEW APPLICATION ENTERED IN TRAM